(Q36148448)

Revision as of 15:45, 14 April 2022 by KrBot (talk | contribs) (‎Changed Asturian label: Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

English

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

multiple sclerosis

0 references

author name string

Lawrence Steinman

1

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

publication date

1 June 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Nature Reviews Drug Discovery

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

510-518

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

https://scigraph.springernature.com/pub.10.1038/nrd1752

0 references

Current disease-modifying therapies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Transcriptional analysis of targets in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Lymphocyte homing and homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

T-Cell Function and Migration — Two Sides of the Same Coin

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Prevention of experimental allergic encephalitis with in vivo administration of anti I-A antibody. Decreased accumulation of radiolabelled lymph node cells in the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

In vivo treatment with anti-alpha4 integrin suppresses clinical and pathological evidence of Borna disease virus infection

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Alpha4beta1 integrin acts as a cell receptor for murine polyomavirus at the postattachment level

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

21 January 2018

Multiple sclerosis: a two-stage disease

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

31 March 2020

Multiple sclerosis: trapped in deadly glue

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

31 March 2020

Evidence for a prolonged role of alpha 4 integrin throughout active experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

31 March 2020

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

31 March 2020

Monoclonal anti-I-A antibody reverses chronic paralysis and demyelination in Theiler's virus-infected mice: critical importance of timing of treatment

1 reference

https://api.crossref.org/works/10.1038%2FNRD1752

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/NRD1752

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36148448&oldid=1618896004"